Komunikaty handlowe

GEA opens a new chapter for biopharmaceutical separation processes with pharma separator lines aseptic and pure

06 Jul 2021

With the introduction of the new separator lines aseptic and pure under the motto "Energizing Pharma", pharmaceutical specialist GEA is ushering in a new era for biopharmaceutical separation processes.

GEA's aseptic separator line offers customers with highly hygienic processes gentle processing of, for example, human and veterinary vaccines, monoclonal antibodies (mAb), e-coli, insulin, starter cultures and probiotic products. (Photo: GEA)

GEA's aseptic separator line offers customers with highly hygienic processes gentle processing of, for example, human and veterinary vaccines, monoclonal antibodies (mAb), e-coli, insulin, starter cultures and probiotic products. (Photo: GEA)

Based on GEA's decades of expertise in the field of mechanical separation technology, GEA engineers have developed a new, fully comprehensive portfolio of plug & produce pharma separator systems that moves harmoniously and perfectly between individual and process-related requirements and leaves nothing to be desired. The separator lines aseptic and pure are used in all pharmaceutical and biotechnological downstream processes. GEA's aseptic separator line offers customers with highly hygienic processes gentle processing of, for example, human and veterinary vaccines, monoclonal antibodies (mAb), e-coli, insulin, starter cultures and probiotic products. The pure line is used in applications with varying hygienic requirements such as nutritional supplements, therapeutic proteins, pharmaceutical extractions, and extracellular and intracellular enzyme recovery.

Perfectly adapted separation solution from GEA

The biopharmaceutical industry is united by a common denominator. It places the highest value on uncompromising hygienic design, process reliability and high yield. However, the detailed requirements can vary widely depending on process regulations and specifications. GEA took this requirement profile as an opportunity to develop a separation solution for the biopharmaceutical industry that is perfectly adaptable in every respect.

Line pure is used in applications with varying hygienic requirements such as dietary supplements, therapeutic proteins, pharmaceutical extractions, and extracellular and intracellular enzyme recovery. (Photo: GEA)

Line pure is used in applications with varying hygienic requirements such as dietary supplements, therapeutic proteins, pharmaceutical extractions, and extracellular and intracellular enzyme recovery. (Photo: GEA)

Development to the highest GEA standards

The new pharmaceutical separator lines "aseptic" and "pure" were developed to the highest GEA standards at the German GEA Westfalia Separator plant in Oelde, where they are built and tested. The aseptic line stands for the highest hygienic pharmaceutical requirements. The pure line provides maximum variability and is perfectly tailored to the diverse process requirements of the biopharmaceutical industry. All functions for pharmaceutical cleanliness requirements such as an automatic CIP (Cleaning-in-Place), SIP (Steam Sterilization in Place), simple validation and a high-end qualification package are included. In addition, with the help of the cGMP validation process ("Current Good Manufacturing Practice, cGMP), the pharma separators support GEA customers in their quality standard reviews.

Contact

Dr. Michael Golek

Phone: 49 211 9136 1505

Media Relations

GEA Group Aktiengesellschaft

Peter-Müller-Str. 12


40468

Düsseldorf


Germany

+49 211 9136-0

O GEA

GEA jest jednym z największych dostawców dla przemysłu przetwarzania żywności i wielu innych sektorów, w 2019 roku spółka wygenerowała skonsolidowane przychody na poziomie 4,9 miliarda euro.

Ta międzynarodowa grupa technologiczna specjalizuje się w produkcji maszyn, instalacji oraz technologii i komponentów procesowych. GEA dostarcza zrównoważone rozwiązania energetyczne na potrzeby skomplikowanych procesów produkcji na różnych rynkach użytkownika końcowego oraz oferuje wszechstronne portfolio usług. Około 70 procent przychodów grupy pochodzi z sektora żywności oraz napojów i alkoholi, w którym obserwowany jest długoterminowy i zrównoważony wzrost. Zgodnie ze stanem na 31 grudnia 2018 roku firma zatrudnia na całym świecie około 18 500 osób. GEA jest liderem rynkowym i technologicznym w segmentach biznesowych, w których prowadzi działalność. Spółka jest notowana na niemieckim indeksie MDAX (G1A, WKN 660 200), indeksie STOXX® Europe 600 Index oraz wybranych indeksach MSCI Global Sustainability. Więcej informacji można uzyskać w witrynie gea.com.
Otrzymuj nowości od GEA

Śledź innowacje i historie GEA, zarejestruj się do biuletynu z wiadomościami od GEA.

Skontaktuj się z nami

Jesteśmy po to, by Ci pomóc! Potrzebujemy kilku informacji, by odpowiedzieć na Twoje zapytanie.